Lymphoma

Patients with mantle cell lymphoma who were treated with Imbruvica had a better quality of life than those treated with another agent, according to the results of a recent study.

A recent study could be practice-changing for the treatment of cutaneous T-cell lymphoma.

ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). This is the first approval the agency received for immunophenotyping on a flow cytometer.

Irene Hutchins, M.D., and her patient Steve Valentine, both accomplished ballroom dancers, made a pact to dance together once he had recovered from late-stage Burkitt lymphoma. They performed their victory dance June 11 during Cancer Survivors Day at Scripps Green Hospital, in La Jolla, California, where Hutchins treated Valentine.

Rituxan Hycela (rituximab) was granted approval by the Food and Drug Administration (FDA) for adult patients with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL) and previously untreated and previously treated chronic lymphocytic leukemia (CLL).

Expert Lisa G. Roth, M.D., discusses the unique needs of AYA patients with Hodgkin lymphoma.

JCAR017 had promising complete response and objective response rates in treating patients with diffuse large B-cell lymphoma (DLBCL) in a recently presented study.

Opdivo had promising response rates in a recent trial testing the treatment in patients with relapsed or refractory Hodgkin lymphoma.

Pairing two drugs that have shown to be effective in treating lymphoma might be the next step for mantle cell lymphoma treatment.

When we are surviving cancer, when we want to see everybody else survive it too, another death is hard to take. When somebody passes, we are reminded of our own mortality—and distant losses—even as we mourn. Poetry helps.

Peter Martin, M.D., discusses the evolving field of mantle cell lymphoma treatment.

Axicabtagene ciloleucel (KTE-C19; axi-cel) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma (NHL).

There is currently no uniform procedure for patients with double-hit lymphoma (DHL) that prolongs benefit. Some patients receive autologous stem-cell transplantation to reduce the risk of relapse, but the jury is still out on the impact that it has.

Copanlisib was granted a priority review designation by the Food and Drug Administratioin (FDA) for the treatment of patients with relapsed/refractory follicular lymphoma who had at least two therapies beforehand, according to Bayer, the manufacturer of the drug.

There were nearly identical response rates and toxicity with subcutaneous administration of Rituxan (rituximab) and IV administration of the drug to treat follicular lymphoma in the first-line setting, according to results from the phase 3 SABRINA trial that were published in The Lancet Haematology.

Experts discuss how to have the best chances for a complete response for patients with chronic lymphocytic leukemia (CLL) who developed Hodgkin lymphoma (HL).

Grzegorz S. Nowakowski, M.D., discusses the potential for genetic testing for patients with mantle cell lymphoma.

How I saved big on costly prescription medications for cancer treatment.

A mantle cell lymphoma survivor discusses being a transplant patient.

The medications that help patients can be dangerous in combination if not closely monitored.

Finding normalcy after cancer.

Novel combinations may be on the rise for the treatment of mantle cell lymphoma.

How food can trigger memories and emotions.

A non-runner explains why running and cancer are the same thing. Except they're not.